# Ne oldu?

The American College of Gastroenterology (ACG) has published a new clinical guideline titled "ACG Clinical Guideline: Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes." The guideline provides evidence-based recommendations for the diagnosis and management of hereditary adenomatous colorectal polyposis syndromes. It focuses on risk assessment, germline genetic testing, endoscopic and surgical interventions, and chemoprevention strategies.

# Ayrıntılar

The guideline addresses the two most common hereditary colorectal polyposis syndromes: familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP). These syndromes are characterized by the growth of numerous adenomatous polyps in the colon and rectum, which significantly increase the risk of colorectal cancer. The recommendations are designed to help clinicians identify at-risk individuals, determine the need for genetic testing, and implement appropriate surveillance and surgical interventions.

Key areas covered include:

• Risk assessment based on personal and family history.
• Modalities and timing of germline genetic testing.
• Cancer risk mitigation through endoscopic surveillance and surgical timing.
• The role of chemoprevention in management.

The guideline utilizes the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to provide clinical guidance. It reviews the phenotypic manifestations of known hereditary syndromes and emphasizes the importance of timely surgical and endoscopic management in reducing cancer incidence and mortality.

# Neden önemli?

This guideline is significant because it standardizes the approach to managing hereditary polyposis syndromes, which are incurable, systemic cancer risk predisposition syndromes with substantial morbidity and mortality. By providing clear recommendations on risk assessment and genetic testing, the ACG aims to facilitate early identification of affected individuals and families. Timely intervention, as recommended, can reduce the likelihood of colorectal cancer development, thereby improving patient outcomes and quality of life. The guideline also addresses the complexity of management based on genetic test results and clinical features, offering a structured framework for clinicians.

# Sırada ne var?

While this guideline establishes a foundation for the management of the two most common syndromes, ongoing research continues to explore rarer polyposis variants and improved genetic testing methodologies. Implementation of these recommendations will depend on individual patient factors, healthcare system resources, and the local availability of genetic testing and endoscopic services. Clinicians are encouraged to integrate these evidence-based recommendations into practice to optimize patient care in the management of adenomatous polyposis syndromes.